Skip to main content
SpringerLink
Log in

Increasing evidence for the safety and efficacy of alcohol septal ablation during medium- and long-term follow-up

  • EDITORIAL
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

ASA:

Alcohol septal ablation

CCS:

Canadian cardiovascular society angina class

ICD:

Implantable cardioverter defibrillator

n:

number

NYHA:

New York Heart association functional class

post:

at the end of the follow-up

pre:

Prior to the procedure

CK:

Creatinine kinase

IVS:

Interventricular septum diameter

LAd:

Left atrial diameter

LVDd:

Left ventricular diastolic diameter

LVEF:

Left ventricular ejection fraction

LVFS:

Left ventricular fractional shortening

LVOT:

Left ventricular outflow tract

LVPW:

Left ventricular posterior wall

ml:

Millilitre

References

  1. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization/ International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93:841–842

    PubMed  CAS  Google Scholar 

  2. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92:785–789

    PubMed  CAS  Google Scholar 

  3. Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308–1320

    Article  PubMed  Google Scholar 

  4. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114:2232–2239

    Article  PubMed  Google Scholar 

  5. Nishimura Ra, Holmes DR Jr (2004) Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med 350:1320–1327

    Article  PubMed  CAS  Google Scholar 

  6. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295– 303

    Article  PubMed  Google Scholar 

  7. Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P (2005) The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 45(7):1076–1080

    Article  PubMed  Google Scholar 

  8. Elliott PM, Gimeno JR, Tome MT, Shah J, Ward D, Thaman R, Mogensen J, McKenna WJ (2006) Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 27(16):1933–1941

    Article  PubMed  Google Scholar 

  9. Robbins RC, Stinson EB (1996) Longterm results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 111(3):586–594

    Article  PubMed  CAS  Google Scholar 

  10. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA (2005) Longterm effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46:470–476

    Article  PubMed  Google Scholar 

  11. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, Siu S, Ralph-Edwards A, Rakowski H (2005) Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 111(16):2033–2041

    Article  PubMed  Google Scholar 

  12. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED (2003) Task force on clinical expert consensus documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. College of Cardiology/ European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42(9):1687–1713

    Article  PubMed  Google Scholar 

  13. Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346(8969):211–214

    Article  PubMed  CAS  Google Scholar 

  14. Kuhn H, Gietzen F, Leuner CH, Gerenkamp T (1997) Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: studies to develop a new catheter-based concept of treatment. Eur Heart J 18:846–851

    PubMed  CAS  Google Scholar 

  15. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-months follow-up in 25 patients. J Am Coll Cardiol 31:252–258

    Article  PubMed  CAS  Google Scholar 

  16. Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98:2415–2421

    PubMed  CAS  Google Scholar 

  17. Gietzen FH, Leuner J, Raute-Kreinsen U, Dellmann AM, Hegselmann J, Strunk-Mueller C, Kuhn HJ (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Eur Heart J 20:1342–1354

    Article  PubMed  CAS  Google Scholar 

  18. Kuhn H, Gietzen FH, Leuner C, Schafers M, Schober O, Strunk-Muller C, Obergassel L, Freick M, Gockel B, Lieder F, Raute-Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89(Suppl 4)4:41–54

    Google Scholar 

  19. Faber L, Seggewiss H, Welge D, Fassbender D, Schmidt HK, Gleichmann U, Horstkotte D (2004) Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr 5(5):347–355

    Article  PubMed  Google Scholar 

  20. Kuhn H, Seggewiss H, Gietzen FH, Boekstegers P, Neuhaus L, Seipel L (2004) Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry. Z Kardiol 93(1):23–31

    Article  PubMed  CAS  Google Scholar 

  21. Faber L, Seggewiss H, Gietzen FH, Kuhn H, Boekstegers P, Neuhaus L, Seipel L, Horstkotte D (2005) Catheter- based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society. Z Kardiol 94(8):516–523

    Article  PubMed  CAS  Google Scholar 

  22. Alam M, Dokainish H, Lakkis N (2006) Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. A systematic review of published studies. J Interv Cardiol 19:319–327

    Article  PubMed  Google Scholar 

  23. Knight CJ (2006) Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Heart 92:1339–1344

    Article  PubMed  Google Scholar 

  24. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Müller C, Kuhn H (2004) Transoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit and short term results in elderly patients. Heart 90:638–644

    Article  PubMed  CAS  Google Scholar 

  25. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JK, Martin M, Tuzcu EM, Smedira NG, Lytle B, Thomas JD (2001) Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy. J Am Coll Cardiol 38(7):1994–2000

    Article  PubMed  CAS  Google Scholar 

  26. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH (2001) Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38: 1701–1706

    Article  PubMed  CAS  Google Scholar 

  27. Ralph-Edwards A, Woo A, McCrindle BW, Shapero JL, Schwartz L, Rakowski H, Wigle ED, Williams WG (2005) Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 129:351–358

    Article  PubMed  Google Scholar 

  28. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, Sachdev B, Thaman R, McKenna WJ (2002) Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. Eur Heart J 23:1617–1624

    Article  PubMed  CAS  Google Scholar 

  29. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ, Nishimura RA (2004) The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 44:2044–2053

    Article  PubMed  Google Scholar 

  30. Haldman AW, Wu KC, Abraham TP, Cameron DE (2007) Myectomy or alcohol septal ablation. J Am Coll Cardiol 49:358–360

    Article  Google Scholar 

  31. Lawrenz T, Obergassel L, Lieder F, Leuner C, Strunk-Mueller C, Meyer Zu Vilsendorf D, Beer G, Kuhn H (2005) Tanscoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 28:295–300

    Article  PubMed  Google Scholar 

  32. Boltwood CM Jr, Chien W, Ports T (2004) Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med 351:1914–1915

    Article  PubMed  CAS  Google Scholar 

  33. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H (2007) One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients. Predictors of hemodynamic and clinical response. Clin Res Cardiol 96:863–872

    Google Scholar 

  34. Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L (2007) Longterm follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 96:855–862

    Google Scholar 

  35. Chang SM, Lakkis NM, Franklin J, Spencer WH 3rd, Nagueh SF (2004) Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 109:824–827

    Article  PubMed  Google Scholar 

  36. Yoerger DY, Picard MH, Palacios IF, Vlahakes GJ, Lowry PA, Fifer MA (2006) Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 97:1511–1514

    Article  PubMed  Google Scholar 

  37. Keren A, Poteckin M, Mazouz B, Medina A, Banai S, Chenzbraun A, Khoury Z, Levin G (2007) Late inhospital pressure gradient measurements improve prediction of longterm outcome of alcohol septal ablation in hypertrophic cardiomyopathy. IMAJ 9:239–242

    PubMed  CAS  Google Scholar 

  38. Schultz-Menger J, Strohm O, Waigand J, Uhlich F, Dietz R, Friedrich MG (2000) The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. Circulation 101:1764–1766

    Google Scholar 

  39. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CS, Schaff HV, Maron BJ (2007) Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hyoertrophic obstructive cardiomyopathy. J Am Coll Cardiol 49:350–357

    Article  PubMed  Google Scholar 

  40. Keren A, Syrris P, McKenna WJ (2008) Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med (in press)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Charité – Universitätsmedizin Berlin, Department of Cardiology and Pneumonology Medizinische Klinik II Campus Benjamin Franklin, Berlin, Germany

    Matthias Pauschinger

  2. Center for Heart Failure and Heart Muscle Diseases, Heart Institute Hadassah University Hospital Hadassah-Hebrew University Medical School, Jerusalem, 91120, Israel

    Andre Keren

Authors
  1. Matthias Pauschinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andre Keren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andre Keren.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pauschinger, M., Keren, A. Increasing evidence for the safety and efficacy of alcohol septal ablation during medium- and long-term follow-up. Clin Res Cardiol 96, 851–855 (2007). https://doi.org/10.1007/s00392-007-0580-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-007-0580-2

Key words

Search

Navigation